Navigation Links
Sandell Asset Management Seeks Sale of Rubicon & Tenon, Expansion of Board
Date:10/10/2011

NEW YORK, Oct. 10, 2011 /PRNewswire/ -- In response to Rubicon's poor stock performance, Sandell Asset Management's Chief Executive Officer Thomas E. Sandell sent today the following letter to Rubicon's Board of Directors:

Board of Directors
Rubicon Limited
Level 3
7 - 9 Fanshawe Street
Auckland
New Zealand
Attn: Steve Kasnet, Chairman
Luke Moriarty, Chief Executive Officer

Dear Gentlemen:

As you are aware, funds managed by Sandell Asset Management Corp. ("Sandell") own approximately 41.1 million shares in Rubicon Limited (RBC NZ) ("Rubicon"), which represent approximately 14.4% of Rubicon's total outstanding shares. As a long-term investor in Rubicon, Sandell has financially and strategically supported Rubicon and its management over the past ten years. However, as we previously indicated to you, following the failure to launch the ArborGen IPO earlier this year, we have lost faith in the ability, or willingness, of Rubicon's current management to take the steps we believe are necessary to enhance shareholder value in the near term.  The company remains significantly undervalued in the public market, and we believe there are several opportunities the company should pursue to maximize shareholder value.

As we have previously indicated to you, we believe that Rubicon should pursue one of the following strategic alternatives to maximize its value: (1) sell Rubicon in its entirety; or (2) sell Rubicon's controlling interest in Tenon pursuant to an auction process, followed by ArborGen listing its shares for trading on the NASDAQ.  When we spoke earlier this year, you indicated that Rubicon could not focus on value-enhancing alternatives until it had addressed several refinancings that were in process at the time.  Those refinancings have been completed, and there should be no other excuse for your failing to promptly consider the strategic alternatives we have proposed.  

In addition, we believe that Rubicon should expand its Board of Directors to include an additional three directors who are representatives of Rubicon's shareholders.  We believe it is critical for the shareholders to have a voice at the board level, to insure that the board is focused on acting in the shareholders' best interest.

Rubicon's stock, after sustaining a loss of nearly 66% this past year, is currently trading at approximately NZD 0.40 per share.  We believe that it is potentially worth upwards of NZD 1.20 per share, or three times its current market value, and that pursuit of the strategies we suggest could achieve a realization of that value.  Furthermore, we believe Rubicon could be worth as much as NZD 1.65 per share based on the values of ArborGen and Tenon as separate strategic targets. On a standalone basis, each of ArborGen and Tenon is a very attractive investment opportunity.  ArborGen is one of the only global biotech companies focused on the genetically modified tree seedling market. This early-mover status has provided ArborGen with a competitive advantage that, with the help of additional equity investments obtained from listing on an exchange, could lead to a tremendous growth opportunity for ArborGen. On the other hand, Tenon is one of the largest vertically-integrated distributors of building products in the U.S. Although Tenon has sustained difficulties in recent years as a result of low levels of large discretionary remodeling activity in the U.S. and the rising NZD:U.S. exchange rate, we believe that there is a large amount of untapped growth that remains available to Tenon, especially in light of macro fundamental indicators that the U.S. housing market is at 40-year lows. A strategic buyer could fund growth and acquisition plans for the business, which should include restructuring Tenon's current operations, launching new do-it-yourself products, reducing costs and expanding into new geographic markets (e.g. China, Europe and Australia).

Enclosed is a white paper presentation containing a more detailed explanation of the strategies that we are recommending Rubicon undertake and a financial analysis of their potential effects.  Please do not hesitate to contact us with any questions you may have. We look forward to continuing our discussions with you and working with Rubicon in pursuing a direction that will maximize the value of the company for all of its shareholders.

Sincerely,

Thomas E. Sandell

Chief Executive Officer

The white paper presentation referenced is available at http://www.sandellmgmt.com/News/Rubicon.pdf or by request.


'/>"/>
SOURCE Sandell Asset Management
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Generex Augments Cash Position With Sales of Non-Essential Assets
2. delSECUR CORPORATION Announces Its Dissolution; and the Distribution of Its Asset to Its Lenders and Shareholders of the Corporation
3. Bacterin International Signs LOI to Acquire Assets of Robinson MedSurg LLC
4. Novogen and Marshall Edwards Sign Asset Purchase Agreement
5. Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets
6. Private Sector Investment in Agriculture Emerging as a Significant Alternative Asset Class: New HighQuest Partners Study
7. Genaera Liquidating Trust To Sell Remaining Proprietary Assets
8. OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock
9. Pharmasset to Webcast an Investor Event from the AASLD Meeting
10. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
11. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Ginkgo Bioworks , a leading organism design company ... as one of the World Economic Forum,s Technology ... companies. Ginkgo Bioworks is engineering biology to manufacture ... the nutrition, health and consumer goods sectors. The ... Fortune 500 companies to design microbes for their ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):